324 related articles for article (PubMed ID: 25522378)
1. DREADD: a chemogenetic GPCR signaling platform.
Zhu H; Roth BL
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25522378
[TBL] [Abstract][Full Text] [Related]
2. Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
Zhu H; Aryal DK; Olsen RH; Urban DJ; Swearingen A; Forbes S; Roth BL; Hochgeschwender U
Genesis; 2016 Aug; 54(8):439-46. PubMed ID: 27194399
[TBL] [Abstract][Full Text] [Related]
3. Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.
Meister J; Wang L; Pydi SP; Wess J
J Neurochem; 2021 Aug; 158(3):603-620. PubMed ID: 33540469
[TBL] [Abstract][Full Text] [Related]
4. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Urban DJ; Roth BL
Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
[TBL] [Abstract][Full Text] [Related]
5. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
[TBL] [Abstract][Full Text] [Related]
6. Targeted Gq-GPCR activation drives ER-dependent calcium oscillations in chondrocytes.
McDonough RC; Gilbert RM; Gleghorn JP; Price C
Cell Calcium; 2021 Mar; 94():102363. PubMed ID: 33550208
[TBL] [Abstract][Full Text] [Related]
7. Use of Designer G Protein-Coupled Receptors to Dissect Metabolic Pathways.
Wess J
Trends Endocrinol Metab; 2016 Sep; 27(9):600-603. PubMed ID: 27381463
[TBL] [Abstract][Full Text] [Related]
8. Gs-DREADD Knock-In Mice for Tissue-Specific, Temporal Stimulation of Cyclic AMP Signaling.
Akhmedov D; Mendoza-Rodriguez MG; Rajendran K; Rossi M; Wess J; Berdeaux R
Mol Cell Biol; 2017 May; 37(9):. PubMed ID: 28167604
[TBL] [Abstract][Full Text] [Related]
9. Targeted Activation of G-Protein Coupled Receptor-Mediated Ca
McDonough RC; Price C
Tissue Eng Part A; 2022 May; 28(9-10):405-419. PubMed ID: 34693731
[TBL] [Abstract][Full Text] [Related]
10. Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis.
Zhang J; Vardy E; Muise ES; Wang TM; Visconti R; Vadlamudi A; Pinto S; Peier AM
J Pharmacol Exp Ther; 2020 Nov; 375(2):357-366. PubMed ID: 32848074
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for selective activation of DREADD-based chemogenetics.
Zhang S; Gumpper RH; Huang XP; Liu Y; Krumm BE; Cao C; Fay JF; Roth BL
Nature; 2022 Dec; 612(7939):354-362. PubMed ID: 36450989
[TBL] [Abstract][Full Text] [Related]
12. Chemogenetic enhancement of functional recovery after a sciatic nerve injury.
Jaiswal PB; English AW
Eur J Neurosci; 2017 May; 45(10):1252-1257. PubMed ID: 28244163
[TBL] [Abstract][Full Text] [Related]
13. G-protein-coupled designer receptors - new chemical-genetic tools for signal transduction research.
Thiel G; Kaufmann A; Rössler OG
Biol Chem; 2013 Dec; 394(12):1615-22. PubMed ID: 23893685
[TBL] [Abstract][Full Text] [Related]
14. Use of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs.
Wang L; Zhu L; Meister J; Bone DBJ; Pydi SP; Rossi M; Wess J
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():421-440. PubMed ID: 32746768
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Tissue-Specific and Temporal Activation of GPCR Signaling Using DREADD Knock-In Mice.
Akhmedov D; Kirkby NS; Mitchell JA; Berdeaux R
Methods Mol Biol; 2019; 1947():361-376. PubMed ID: 30969428
[TBL] [Abstract][Full Text] [Related]
16. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
Aldrin-Kirk P; Björklund T
Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
[TBL] [Abstract][Full Text] [Related]
17. Engineered GPCRs as tools to modulate signal transduction.
Pei Y; Rogan SC; Yan F; Roth BL
Physiology (Bethesda); 2008 Dec; 23():313-21. PubMed ID: 19074739
[TBL] [Abstract][Full Text] [Related]
18. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
Campbell EJ; Marchant NJ
Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
[TBL] [Abstract][Full Text] [Related]
19. Chronic hM4Di-DREADD-Mediated Chemogenetic Inhibition of Forebrain Excitatory Neurons in Postnatal or Juvenile Life Does Not Alter Adult Mood-Related Behavior.
Tiwari P; Kapri D; Pradhan A; Balakrishnan A; Chaudhari PR; Vaidya VA
eNeuro; 2022; 9(1):. PubMed ID: 35115382
[TBL] [Abstract][Full Text] [Related]
20. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
Burnett CJ; Krashes MJ
J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
